華大九天(301269.SZ):目前已成為國內規模最大、產品線最完整、綜合技術實力最強的EDA企業
格隆匯1月10日丨有投資者於投資者互動平台向華大九天(301269.SZ)提問,“在整體經濟下行壓力下,貴司未來還能否保持高速度增長的趨勢?”,公司回覆稱,華大九天EDA工具軟件產品和相關服務已廣泛獲得客户認可,與國內外主要集成電路設計企業、晶圓製造企業、封裝企業、平板廠商建立了良好的業務合作關係。經過多年發展,公司目前已成為國內規模最大、產品線最完整、綜合技術實力最強的EDA企業。公司將進一步加快技術創新步伐,努力提升產品市場競爭力,積極開拓新市場,不斷擴大市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.